expecting upgrades to roll in. imho.
myriad will have the only brca test that will be linked with the critical parp testing trials. doubt that other brca providers will get any of this slice of the pie as suggested in this article (especially if myriad's test is fda approved for this indication!!):
Life After Pfizer: AstraZeneca Hopes for Oncology Success
By Todd Campbell June 3, 2014
agree the worm is turning: 04:55 EDT MYGN, MYGN Myriad Genetics management to meet with Piper Jaffray
Meetings to be held in Minneapolis/Milwaukee/Chicago May 29-30 hosted by Piper Jaffray......... "Piper notes traffic for Quest and LabCorp booths was lower than Myriad, which it called the "clear winner" among the BRCA test providers."
Net - "Jolie isn’t the only celebrity to have tested positive for BRCA1 and undergo a mastectomy. Sharon Osbourne also got the surgery as a preventative measure last November. While Jolie and many women who test positive for the BRCA mutation may be justified in undergoing invasive and expensive surgery to remove their breast tissue or reproductive organs, some worry that it may compel other women to seek out unnecessary surgeries."
Source: Dr. OZ show blog.. can't post link but should show up on Google Search......
Should You Get Surgery to Prevent Cancer?
Women who test positive for the BRCA mutation and are at high risk of getting breast cancer sometimes choose to get a preventive double mastectomy. This elective surgery substantially lowers a woman’s likelihood of developing breast cancer. What is the BRCA mutation? Could you have it? What should you do if you test positive for it? Posted on 5/15/2013
net, the tape seems to support your trickle up theory rather than a rush for the exits at this time. agree that short thesis is still dead. it may help to have a "piper" playing that "tune" on their "flute" as well.
from Nov 2012 article - Sharon would make a great spokesperson for MyRisk as she had COLON CANCER and found to be + for BRCA year later......................multigene panel testing is where this is headed........................
Former X Factor judge Sharon Osbourne has revealed she underwent a preventive double mastectomy after finding she had a genetic mutation that raised her chances of developing breast cancer.
The wife of heavy metal star Ozzy, whose struggles with colon cancer 10 years ago were documented in the reality television show The Osbournes, said the surgery was a "no-brainer" once doctors told her about the flaw.
"As soon as I found out I had the breast cancer gene, I thought: 'The odds are not in my favour,'" Osbourne, 60, told Hello! magazine. "I've had cancer before and I didn't want to live under that cloud: I decided to just take everything off, and had a double mastectomy."
he Percentage Price Oscillator (PPO) is a momentum oscillator that measures the difference between two moving averages as a percentage of the larger moving average. The signals associated with MACD are the same in PPO, so you could say The PPO is a percentage version of the MACD. Buy/sell situations, as in the below HPQ chart, are still triggered on zero line crossovers (1), signal line crossovers (2), PPO/Price divergence (3) and PPO histogram divergence's (4). So PPO, as MACD, is a momentum change indicator.
SALT LAKE CITY, Utah, June 10, 2014 – Crescendo Bioscience, a wholly-owned subsidiary of Myriad Genetics, Inc. (NASDAQ: MYGN), today announced that Vectra® DA data will be featured in eight posters at the 2014 European League Against Rheumatism (EULAR) Annual Meeting, June 11-14, 2014, in Paris, France. Vectra DA is a quantitative, objective multi-biomarker test to measure disease activity in patients with rheumatoid arthritis (RA). The Vectra DA test offers insight into the biological processes that drive disease activity to help rheumatologists manage RA and improve patient care.
At EULAR, data will be presented by researchers from the Swedish Farmacotherapy (SWEFOT) clinical trial that demonstrate the clinical utility of Vectra DA in assessing the risk of future joint damage at multiple points in time. Additionally, SWEFOT data indicate that changes in Vectra DA scores were associated with favorable response to both non-biologic and biologic therapies. Further, the data demonstrate that Vectra DA may have the potential to serve as an inclusion criterion for assessing patients who are candidates for clinical trials in rheumatoid arthritis.